论文部分内容阅读
考察了膦甲酸钠对硫酸头孢噻利在大鼠体内药动学的影响。健康Wistar大鼠随机分为试验组与对照组,每组20只。试验组大鼠尾静脉注射膦甲酸钠360 mg/kg,随后即刻注射硫酸头孢噻利200 mg/kg;对照组仅注射硫酸头孢噻利200 mg/kg。采用HPLC法测定血浆中硫酸头孢噻利浓度,并拟合药动学参数,试验组和对照组结果如下:t1/2(1.76±0.57)和(1.22±0.51)h,cmax(1 314.37±196.70)和(1 470.18±321.38)μg/ml,AUC0→24 h(863.19±189.46)和(799.57±203.39)μg·h·ml-1,AUC0→∞(898.81±214.25)和(800.02±207.04)μg·h·ml-1,V(0.56±0.18)和(0.45±0.17)L/kg,CL(0.23±0.05)和(0.27±0.07)L·h-1·kg-1。合用膦甲酸钠后,硫酸头孢噻利在大鼠体内的t1/2和V显著升高,表明膦甲酸钠与硫酸头孢噻利可能竞争同一排泄途径,减缓硫酸头孢噻利的排泄。
The effect of foscarnet on the pharmacokinetics of ceftiofur sulfate in rats was investigated. Healthy Wistar rats were randomly divided into experimental group and control group, 20 rats in each group. The rats in the experimental group were injected foscarnet sodium 360 mg / kg into the caudal vein, followed by immediate injection of ceftizurium sulfate 200 mg / kg. The control group was injected only with cefalir sulfate 200 mg / kg. The concentration of cefoselis sulfate in plasma was determined by HPLC and the pharmacokinetic parameters were fitted. The results of test group and control group were as follows: t1 / 2 (1.76 ± 0.57) and (1.22 ± 0.51) h, cmax (1314.37 ± 196.70 ) And AUC0 → 24 h (863.19 ± 189.46) and (799.57 ± 203.39) μg · h · ml-1, AUC0 → ∞ (898.81 ± 214.25) and (800.02 ± 207.04) μg / · H · ml -1, V (0.56 ± 0.18) and (0.45 ± 0.17) L / kg, CL (0.23 ± 0.05) and (0.27 ± 0.07) L · h -1 · kg -1, respectively. When combined with foscarnet, t1 / 2 and V in rats were significantly increased, indicating that foscarnet and sodium cefotaxime may compete for the same excretion pathway and slow the excretion of cefoselis sulfate.